Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pain control for bone metastasis using radioactive strontium].

Keiichirou Yamaguchi1

  • 1Department of Radiology, Sendai Kousei Hospital, Sendai, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 16, 2010
PubMed
Summary

Radioactive strontium (89Sr) therapy effectively reduced pain in cancer patients, decreasing opiate use for up to three months. Careful patient selection is crucial to minimize side effects and optimize palliative care outcomes.

Related Concept Videos

Blood and Nerve Supply to the Bones01:29

Blood and Nerve Supply to the Bones

Bones are dynamic organs that require a rich supply of oxygen and nutrients. Around 5% to 10% of the cardiac output supplies blood to the bones. A typical long bone has three main sources: the nutrient artery, the metaphyseal and epiphyseal arteries, and the periosteal arteries.
Nutrient Artery
The nutrient artery is the main blood vessel that enters the diaphysis via the nutrient foramen. While most long bones have only one nutrient foramen, large bones, such as the femur, may have two. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin G4-related constrictive pericarditis identified by cytological examination of pericardial effusion: a case report.

Journal of medical case reports·2016
Same author

FDG PET and gallium scintigraphy for diagnosis of an advanced jejunal adenocarcinoma with distant metastases.

Clinical nuclear medicine·2004
Same author

Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2003
Same author

[Performance evaluation of dual-head coincidence gamma camera for positron imaging].

Kaku igaku. The Japanese journal of nuclear medicine·2002

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Palliative Care

Background:

  • Cancer pain management remains a significant clinical challenge.
  • Palliative radiotherapy offers a treatment option for pain relief.
  • Radioactive strontium (89Sr) is a beta-emitting radiopharmaceutical used for palliation.

Purpose of the Study:

  • To evaluate the efficacy and safety of palliative therapy using radioactive strontium (89Sr) in cancer patients.
  • To identify patient subgroups that benefit most from 89Sr therapy.
  • To assess the impact of repeated 89Sr administration and identify contraindications.

Main Methods:

  • Sixty cancer patients received palliative therapy with radioactive strontium (89Sr).
  • Pain reduction, opiate/analgesic use, and duration of pain relief were assessed.

Related Experiment Videos

  • Side effects, including hematological parameters, were monitored.
  • Image diagnosis (bone scan) and specific clinical factors were used to determine indications and contraindications.

    • Main Results:

    • Seventy-one percent of patients reduced or stopped opiate/analgesic use.
    • Pain relief lasted up to three months, with notable efficacy in breast and prostate cancer patients.
    • Lung cancer patients showed limited pain reduction.
    • Repeated 89Sr administration maintained pain relief but caused mild, transient decreases in hemoglobin, WBC, and platelets.
    • Contraindications include DIC, renal failure, poor 99mTc-MDP uptake, rapidly progressive disease, radiculopathy, and soft tissue invasion.

    Conclusions:

    • Radioactive strontium (89Sr) is an effective palliative treatment for cancer pain, reducing opioid requirements.
    • Patient selection based on imaging and clinical factors is critical for optimizing outcomes and minimizing risks.
    • Current use is limited to end-stage patients; future applications may involve earlier stages combined with chemotherapy.